Background: Hypertension is a risk factor for cardiovascular disease, and the prevalence of hypertension tends to increase with age. Current treatments for hypertension have adverse side effects and poor adherence. The purpose of this study is to evaluate the effects of moxibustion on blood pressure in individuals with pre- or stage I hypertension.
Methods/design: Forty-five subjects with pre- or stage I hypertension will be randomized into three groups: treatment group A (2 times/week), treatment group B (3 times/week), and the control group (non-treated group). The inclusion criteria will be as follows: (1) aged between 19 and 65 years; (2) prehypertension or stage I hypertension (JNC 7, Seventh Report of the Joint National Committee on the Prevention, Detection, Evaluation, and Treatment of High Blood Pressure); (3) the participants are volunteers and written consent obtained.The participants in the treatment group A will undergo indirect moxibustion 2 times per week for 4 weeks, and the participants in the treatment group B will undergo indirect moxibustion 3 times per week for 4 weeks. The participants in the control group (non-treated group) will maintain their current lifestyle, including diet and exercise. The use of antihypertensive medication is not permitted. The primary endpoint will be a change in patient blood pressure. The secondary endpoints will be the body mass index, lipid profile, EuroQol and Heart Rate Variability. The data will be analyzed with the Student's t-test and analysis of variance (ANOVA) (p < 0.05).
Discussion: The results of this study will help to establish the optimal approach for the care of adults with pre- or stage I hypertension.
Trial Registration: Clinical Research Information Service KCT0000469.
Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3561138 | PMC |
| http://dx.doi.org/10.1186/1745-6215-13-188 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Insights in biomarkers complexity and routine clinical practice for the diagnosis of thyroid nodules and cancer.
PeerJ
January 2025
Instituto de Patologia e Imunologia Molecular da Universidade do Porto (IPATIMUP), i3S-Institute for Research & Innovation in Health, Porto, Portugal.
Background: The differential diagnosis between benign and malignant thyroid nodules continues to be a major challenge in clinical practice. The rising incidence of thyroid neoplasm and the low incidence of aggressive thyroid carcinoma, urges the exploration of strategies to improve the diagnostic accuracy in a pre-surgical phase, particularly for indeterminate nodules, and to prevent unnecessary surgeries. Only in 2022, the 5th WHO Classification of Endocrine and Neuroendocrine Tumors, and in 2023, the 3rd Bethesda System for Reporting Thyroid Cytopathology and the European Thyroid Association included biomarkers in their guidelines.
View Article and Find Full Text PDFNeurobehavioural Exploration of Breath-counting & Breath-awareness in Novice Indian Meditators: A Naturalised Ānāpānasati-based Paradigmatic Approach.
Ann Neurosci
January 2025
National Resource Centre for Value Education in Engineering, Indian Institute of Technology, Delhi, India.
Background: Neural activity and subjective experiences indicate that breath-awareness practices, which focus on mindful observation of breath, promote tranquil calm and thoughtless awareness.
Purpose: This study explores the impact of tristage Ānāpānasati-based breath meditation on electroencephalography (EEG) oscillations and self-reported mindfulness states in novice meditators following a period of effortful cognition.
Methods: Eighty-nine novice meditators (82 males; Mean Age = 24.
Effects of transcutaneous electric nerve stimulation on pain after episiotomy. A systematic review and meta-analysis.
Heliyon
January 2025
Faculty of Physiotherapy, University of Vigo, Pontevedra, Spain.
Background: Episiotomy is a surgical intervention performed during the second stage of labor to facilitate the baby's exit through the birth canal. There are different reasons that lead episiotomy; however, it is recommended performed occasionally and not systematically, since it may produce negative effects such as pain. Different therapies have been described to reduce this pain, including transcutaneous electrical nerve stimulation (TENS).
View Article and Find Full Text PDFOutcomes in stage IIA versus stage IIB/III in the PALLAS trial [ABCSG-42/AFT-05/PrE0109/BIG-14-13]).
Breast Cancer Res
January 2025
Austrian Breast & Colorectal Cancer Study Group (ABCSG), Vienna, Austria.
Background: The PALLAS trial investigated the addition of palbociclib to standard adjuvant endocrine therapy to reduce breast cancer recurrence. This pre-specified analysis was conducted to determine whether adjuvant palbociclib benefited patients diagnosed with lower risk stage IIA disease compared to those with higher stage disease.
Methods: PALLAS was an international, multicenter, randomized, open-label, phase III trial, representing a public-private partnership between Pfizer, the Austrian Breast Cancer Study Group, and the U.
Supplementation with essential amino acids in the early stage of carbohydrate reintroduction after a very-low energy ketogenic therapy (VLEKT) improves body cell mass, muscle strength and inflammation.
J Transl Med
January 2025
Dipartimento di Psicologia e Scienze della Salute, Università Telematica Pegaso, Centro Direzionale, Via Porzio, Isola F2, Naples, 80143, Italy.
Background: Although little is yet known about the long-term maintenance of very low-energy ketogenic therapy (VLEKT) effects on body composition, muscle strength and inflammation, it is plausible to assume that changes may occur, particularly during the steps following the ketogenic step, due to the loss of the protective effects of ketones and the concomitant reintroduction of carbohydrates. For this reason, the present study aimed to evaluate the effects of supplementation with 8 g per day of essential amino acids (EAAs) on these parameters.
Methods: A total of 68 women of reproductive age and with grade I obesity who had completed 45 days of the ketogenic phase with VLEKT (KeNuT protocol) and 40 days of non-ketogenic phase of KeNuT protocol with VLEKT (phase 3, fruit reintroduction) were included in the study.
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!